To test the use of platelet rich plasma in melasma

Not Applicable

Completed

• Conditions: Health Condition 1: L811- Chloasma

• Registration Number: CTRI/2018/06/014584
• Lead Sponsor: Department of Dermatology

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Completion: 2019-08-30
• Last Update Posted: 24 November 2021

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 40

Inclusion Criteria

1.Patients with clinical diagnosis of melasma

Exclusion Criteria

1. Patients with known platelet dysfunction syndrome, critical thrombocytopenia ( <50,000/ul), any hemodynamic instability or with hemoglobin level < 10 g/dl.

2. Patients with local inflammatory skin disorders or active herpes infection at the site of the procedure.

3. Patients with corticosteroid injection at treatment site within 1 month or systemic use of corticosteroids within 2 weeks.

4. Patients diagnosed with cancer especially hematopoietic or of bone.

5. Patient with known hypersensitivity to platelet rich plasma or any other form of blood components.

6. Patients with any other facial dermatoses.

7. Patients on anticoagulants, oral contraceptive pills, hormone replacement therapy, NSAIDs, antiepileptic medications, isotretinoin or any other phototoxic medication.

8. Pregnancy and lactation.

Study & Design

• Study Type: Interventional
• Study Design: Not specified